

Date: 2nd July 2021

DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION

Daptomycin 350 mg and 500 mg Powder for Solution for Injection/Infusion (Daptomycin): Interim Supply of German Stock to Mitigate Supply Disruption

Dear Healthcare Professional,

Summary: Dr. Reddy's is currently experiencing supply disruption with Daptomycin 350 mg and 500 mg Powder for Solution for Injection/Infusion in the UK.

To ensure continuity in supply, Dr. Reddy's has obtained approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to supply German product (batch number K210131 (350 mg) and K210073 (500 mg); 960 packs per batch), which has been repackaged in UK livery and is expected to be on the UK market from 20/07/2021 and 01/08/2021 respectively.

Please note the following:

- This product is considered licensed in the UK.
- The product from Germany has the same formulation as the UK product
- The product from Germany is manufactured according to the same manufacturing process and quality controls as the UK product.
- There are no differences between product information of the repackaged German product and the UK product.
- The UK product information will be supplied with the product.
- For additional copies of the leaflet, please refer to MHRA website or contact the company contact point (see below).
- The MHRA has approved this product under a batch specific variation to the marketing authorisation.

Please ensure all relevant staff are made aware of the content of this letter and that the information is communicated to the patients.

Call for reporting

Healthcare professionals are asked to report any suspected adverse reactions to the Yellow Card Scheme electronically. Report via the website <https://www.gov.uk/yellowcard>, the free Yellow Card app available from the [Apple App Store](#) or [Google Play Store](#), and some clinical IT systems (EMIS, SystemOne, Vision, MiDatabank) for healthcare professionals. Suspected side effect can also be reported by calling 0800 731 6789 for free.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, treatment dates, and product brand name.

Company contact point

If you have any questions about this letter or require more information about Daptomycin 350 mg and 500 mg Powder for Solution for Injection/Infusion, please contact us by telephone at 01748 828873 or <http://www.drreddys.com/united-kingdom>